BioHarvest Sciences Inc. (BHST) Reports Q3 Loss, Misses Revenue Estimates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 26 2024
0mins
Source: NASDAQ.COM
Quarterly Performance: BioHarvest Sciences Inc. reported a quarterly loss of $0.16 per share, significantly worse than the expected loss of $0.05, and revenues of $6.54 million, missing estimates by 2.26%. The company has only surpassed consensus EPS estimates once in the last four quarters.
Market Outlook: Despite underperforming compared to the S&P 500 this year, the stock holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market. Future performance will depend on management's commentary and earnings estimate revisions.
Analyst Views on BHST
Wall Street analysts forecast BHST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BHST is 13.00 USD with a low forecast of 12.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.610
Low
12.00
Averages
13.00
High
14.00
Current: 5.610
Low
12.00
Averages
13.00
High
14.00
No data
About BHST
BioHarvest Sciences Inc. is a botanical synthesis company. The Company leverages its patented technology process to grow plant-based molecules, without the need to grow the underlying plant. It is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two business verticals: as a contract development and production organization on behalf of customers seeking complex molecules, and as a creator of nutraceutical health and wellness products, which include dietary supplements. Its segments include Nutraceuticals and Pharmaceuticals. VINIA is a red grape cell-based supplement, which is a commercial nutraceutical product derived from the Botanical Synthesis platform and is clinically proven to improve blood flow, which enhances physical energy and mental alertness. VINIA contains multiple polyphenols, including Piceid Resveratrol, which is 25x more soluble in water than regular resveratrol.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
